Business
Cosmo Announces Launch of Winlevi(R) for Treatment of Acne in Singapore and Malaysia
Dublin, Ireland--(Newsfile Corp. - July 17, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-driven healthcare and specialty pharmaceuticals, is pleased to announce the launch of Winlevi® (clascoterone) cream 1% in Singapore and Malaysia, marking its first entry into Southeast Asia through the partnership with Hyphens Pharma International Limited (“Hyphens Pharma”). Winlevi® is a topical ...
About this update from Cosmo Pharmaceuticals Nv
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":1,"height":1,"url":"https://api.newsfilecorp.com/newsinfo/259110/202"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/x.8eiAKuQQ0EpD0hXWJpRg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2O2g9MzY7Y2Y9d2VicA--/https://api.newsfilecorp.com/newsinfo/259110/202","width":1,"height":1}},"lazy":false},{"type":"text","content":"Dublin, Ireland--(Newsfile Corp. - July 17, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-driven healthcare and specialty pharmaceuticals, is pleased to announce the launch of Winlevi® (clascoterone) cream 1% in Singapore and Malaysia, marking its first entry into Southeast Asia through the partnership with Hyphens Pharma International Limited (“Hyphens Pharma”). Winlevi® is a topical treatment for acne vulgaris in patients aged twelve years and older, marking a significant milestone in the commitment of both companies to providing innovative, patient-focused dermatology solutions.","length":612,"tagName":"p"},{"type":"text","content":"Winlevi® is the first topical acne treatment in over 40 years with a first-in-class mechanism of action. Its active ingredient, clascoterone, is the first commercially available topical androgen receptor inhibitor acting directly in the sebaceous glands with no systemic anti-androgen effects; as such, it can be used safely in both males and females. This approach is believed to help reduce sebum production and intervene early in acne pathogenesis. Two identical Phase III studies demonstrated that clascoterone cream 1%, applied topically twice daily for twelve weeks, was more effective than the application of vehicle cream in achieving the Investigator’s Global Assessment (IGA) of success, reducing non-inflammatory lesion count (NILC) and inflammatory lesion count (ILC) in patients with facial acne vulgaris. Clascoterone cream 1% was found to be generally well tolerated.","length":882,"tagName":"p"},{"type":"text","content":"As part of the agreement signed in December 2022, Hyphens Pharma has in-licensed the product from Cosmo Pharmaceuticals for distribution across ten Southeast Asian countries (Singapore, Malaysia, Indonesia, Philippines, Vietnam, Thailand, Brunei, Cambodia, Laos and Myanmar), bringing this innovative therapy first to Singapore and Malays...